PRINCETON (NEW JERSEY, US) / HYDERABAD / MUMBAI / RAJKOT - In a regulatory update as submitted to the Indian Stock Exchanges, Hyderabad headquartered pharmaceutical products manufacturing Indian company Dr Reddy's Laboratories said of launching Colchicine Tablets in the US market, Colchicine Tablets are used to treat severe joint pains in the US Market.
In a press-release titled, "Dr. Reddy's Laboratories announces the launch of ColchicineTablets USP, 0.6 mg in the U.S. Market", as enclosed and attached with the regulatory filing as submitted by the company to the Indian Bourses, it further read that, Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys® (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Colcrys® brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
Dr. Reddy's Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.
You can access and/or read the above narrated news-report on our : BLOG and/or WEBSITE.
In case, if you wish to VERIFY, the above narrated news-report, please CLICK here.
No comments:
Post a Comment